Clinical Trials
Braintumor Website

 For People with Newly Diagnosed Glioblastoma Multiforme
A Study of ABT-414 in Subjects With Newly Diagnosed Glioblastoma (GBM)
With Epidermal Growth Factor Receptor (EGFR) Amplification

 For People with Reccurent Glioblastoma Multiforme (and other malignant gliomas)
A Study of ABT-414 in Adult or Pediatric Subjects With Recurrent Glioblastoma (GBM) With Epidermal Growth Factor Receptor (EGFR) Amplification
Convection-Enhanced Delivery (CED) of MDNA55 in Adults With Glioblastoma at First Recurrence or Progression
Aldoxorubicin Trial for recurrent GBM.

These trials were the most recently added or updated

NCT Trial Name# of CentersLast Updated

NCT03451799

  Ketogenic Diet in Combination With Standard-of-care Radiation and Temozolomide for Patients With Glioblastoma
108/27/2018

NCT03234595

  A Phase I/IIa Study of Cerebraca Wafer Plus Adjuvant Temozolomide (TMZ) in Patients With Recurrent High Grade Glioma
108/27/2018

NCT03213704

  Larotrectinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With NTRK Fusions (A Pediatric MATCH Treatment Trial)
508/27/2018

NCT03033992

  Feasibility Trial of Optune for Children With Recurrent or Progressive Supratentorial High-Grade Glioma and Ependymoma
908/27/2018

NCT02978404

  Combining Radiosurgery and Nivolumab in the Treatment of Brain Metastases
108/27/2018

NCT02974621

  Cediranib Maleate and Olaparib Compared to Bevacizumab in Treating Patients With Recurrent Glioblastoma
908/27/2018

NCT02831959

  Effect of TTFields (150 kHz) in Non-small Cell Lung Cancer (NSCLC) Patients With 1-10 Brain Metastases Following Radiosurgery (METIS)
8508/27/2018

NCT02781792

  Temozolomide Chronotherapy for High Grade Glioma
108/27/2018

NCT02704858

  Safety and Efficacy Study in Recurrent Grade IV Glioma
308/27/2018

NCT02617589

  An Investigational Immuno-therapy Study of Nivolumab Compared to Temozolomide, Each Given With Radiation Therapy, for Newly-diagnosed Patients With Glioblastoma (GBM, a Malignant Brain Cancer)
3408/27/2018

NCT02133183

  Sapanisertib Before and After Surgery in Treating Patients With Recurrent Glioblastoma
708/27/2018

NCT03247127

  Memory Preservation of Hippocampal Avoidance Whole Brain Radiotherapy
108/26/2018

NCT03538587

  Feasibility and Preliminary Efficacy of a Mindfulness-based Intervention for Children With High Grade Brain Tumors and Their Caregivers
108/25/2018

NCT03493932

  Cytokine Microdialysis for Real-Time Immune Monitoring in Glioblastoma Patients Undergoing Checkpoint Blockade
108/25/2018

NCT03412877

  Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Mutated Neoantigens in People With Metastatic Cancer
108/25/2018

NCT03632317

  A Study of Panobinostat in Combination With Everolimus for Children and Young Adults With Gliomas
108/24/2018

NCT03526250

  Palbociclib in Treating Patients With Relapsed or Refractory Rb Positive Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating Alterations in Cell Cycle Genes (A Pediatric MATCH Treatment Trial)
3508/24/2018

NCT03058289

  A Phase 1/2 Safety Study of Intratumorally Dosed INT230-6
608/24/2018

NCT02915744

  A Study of Etirinotecan Pegol (NKTR-102) Versus Treatment of Physician's Choice (TPC) in Patients With Metastatic Breast Cancer Who Have Stable Brain Metastases and Have Been Previously Treated With an Anthracycline, a Taxane, and Capecitabine
6608/24/2018

NCT02780804

  Entinostat in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors
1708/24/2018

NCT02359565

  Pembrolizumab in Treating Younger Patients With Recurrent, Progressive, or Refractory High-Grade Gliomas, Diffuse Intrinsic Pontine Gliomas, Hypermutated Brain Tumors, Ependymoma or Medulloblastoma
408/24/2018

NCT03606161

  Navigated Repetitive Transcranial Magnetic Stimulation in Improving Motor Rehabilitation in Participants With Grade II-IV Brain Tumors
108/23/2018

NCT03382977

  Study to Evaluate Safety, Tolerability, and Optimal Dose of Candidate GBM Vaccine VBI-1901 in Recurrent GBM Subjects
308/23/2018

NCT01922076

  WEE1 Inhibitor AZD1775 and Local Radiation Therapy in Treating Children With Newly Diagnosed Diffuse Intrinsic Pontine Gliomas
1808/23/2018



Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2018 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740